Deerland Probiotics and Enzymes, as the company is now formally known, is based in Kennesaw, GA. The company announced in October of 2019 that it had acquired Bifodan, which manufactures probiotics as well private label dietary supplements, medical devices and OTC drugs.
The now fully integrated pairing will operate in more that 40 countries, said Deerland CEO Scott Ravech.
"We are excited to unleash the power of two organizations, now operating as one elite global solutions provider. Together, we are one step closer to achieving our vision of all people of all cultures benefiting from our enzyme, probiotic and prebiotic health products and science-backed technologies,” Ravech said.
At the time of the Bifodan acquisition, the details of which were not announced, industry observer Grant Ferrier, founder of Nutrition Capital Network, had this to say about the development:
“This is a sign of increasing globalization in the nutritional ingredient supply business. Historically, we saw a wave of partnerships with Asia for lower cost supply of commodity ingredients and then we mostly saw European companies taking more leadership on larger specialty ingredients like fish oils and probiotics. Now we’re seeing more North American-based global players partnering with European technology leaders as evidenced by this transaction.”
“Deerland has become a more aggressive and ambitious broad-based global supplier and developer of proprietary ingredient products. The company had a strong position in enzymes but obviously probiotics is an adjacent category that has lots of synergies in terms of customer relationships,” Ferrier added.